At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...

D Molecular Therapeutics (FDMT) offers attractive growth potential with strong cash reserves and promising late-stage gene therapy programs. See more here.

Justis Ehlers, MD, spoke with Ophthalmology Times to share key findings from his recent presentation at the 2025 Retina Society meeting, which was held in Chicago, Illinois.

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch next year.

The therapy is expected to block abnormal blood vessel growth, limit vascular leakage, and reduce retina damage. The Food and Drug Administration (FDA) has granted Fast Track designation to SAR402663 ...

SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals ...

An mRNA vaccine developed by researchers from Japan suppressed abnormal blood vessel growth or neovascularization in the retina of mouse models. Neovascularization is a condition that is caused by age ...

Onconic Therapeutics has initiated a clinical trial for a combination therapy that could change the global paradigm for ovarian cancer treatment. On October 1, Onconic Therapeutics announced that it ...

A new mRNA vaccine developed in Japan has been shown to suppress abnormal blood vessel growth in the retina of mice, offering hope for patients with age-related macular degeneration (AMD).

From a small team of researchers and skipped salaries, CEO Michelle Xia has steered Akeso to become one of the most exciting companies in the industry today.